Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Fresolimumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions
- 12 Jul 2017 Planned End Date changed from 1 Apr 2019 to 1 Aug 2019.
- 12 Jul 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.